RESUMEN
OBJECTIVES: The aim of this study is to conduct a cost-utility analysis of the use of the antiviral nirmatrelvir/ritonavir, applied to a vaccinated Brazilian population against COVID-19, from the perspective of the Brazilian Public Health System (SUS). METHODS: A microsimulation model was created with individual-level data and daily cycles, with a 1-year time horizon, to compare the current scenario of standard care with a scenario in which nirmatrelvir/ritonavir is offered to the population. Adults of any age group that received ≥2 doses of the COVID-19 vaccine formed the investigated population. Direct medical costs of the outpatients and inpatients admitted to the ward or intensive care unit were included. The effectiveness of the model was measured in quality-adjusted life-years (QALYs). RESULTS: In all simulations, the use of nirmatrelvir/ritonavir resulted in incremental costs per patient of US dollar (USD)245.86 and incremental effectiveness of 0.009 QALY, over a year. The incremental cost-utility ratio was USD27 220.70/QALY. The relative risk of the vaccinated population was the factor that affected the outcome most, according to the univariate sensitivity analysis. The probabilistic sensitivity analysis resulted in 100% of the simulations being more costly and effective, but that only 4% of them were below the established cost-effectiveness threshold of USD24 000.00/QALY. In the scenario considering only the population over 60 years old and immunosuppressed (of any age), the incremental cost-utility ratio was USD7589.37/QALY. CONCLUSIONS: The use of nirmatrelvir/ritonavir in the treatment of COVID-19 in a vaccinated population was cost-effective only for immunosuppressed individuals and people over 60 years of age.
Asunto(s)
COVID-19 , Lactamas , Leucina , Nitrilos , Prolina , Ritonavir , Adulto , Humanos , Persona de Mediana Edad , Anciano , Ritonavir/uso terapéutico , Brasil , Vacunas contra la COVID-19/uso terapéutico , COVID-19/prevención & controlRESUMEN
Security is one of the most imperative requirements for the success of systems that deal with highly sensitive data, such as medical information. However, many existing mobile health solutions focused on collecting patients' data at their homes that do not include security among their main requirements. Aiming to tackle this issue, this paper presents SecourHealth, a lightweight security framework focused on highly sensitive data collection applications. SecourHealth provides many security services for both stored and in-transit data, displaying interesting features such as tolerance to lack of connectivity (a common issue when promoting health in remote locations) and the ability to protect data even if the device is lost/stolen or shared by different data collection agents. Together with the system's description and analysis, we also show how SecourHealth can be integrated into a real data collection solution currently deployed in the city of Sao Paulo, Brazil.